ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO524

Unusual Autosomal Dominant Transmission of NPHS2 Variant

Session Information

  • Genetic Diseases: Diagnosis
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

  • 1102 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • La Porta, Edoardo, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Caridi, Gianluca, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Angeletti, Andrea, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Lugani, Francesca, Istituto Giannina Gaslini, Genova, Liguria, Italy

Group or Team Name

  • IRCCS Istituto Giannina Gaslini
Introduction

NPHS2 encodes for podocin, a protein necessary to the structure of the slit diaphragm. NPHS2 variants are associated with autosomal recessive SRNS. C- terminal part of podocin is responsible for the protein oligomerization (DOI: 10.1007/s10157-016-1331-39) and heterozygous LoF variants of this region can lead to protein retention in the cell cytoplasm, causing a dominant-negative effect similar to the recessive condition. Two families with AD glomerulopathy and C-terminal LoF of the podocin have been described (Seidl, D. Nephrol Dial Tranplant 2022 37:suppl3; MO044). We identified a family with a heterozygous frameshift variant of NPHS2 on exon 8 segregating in all affected members tested.

Case Description

A 4 years old male was investigated for proteinuria. Family history underlined 4 generations of affected family members following an AD transmission. Father (III:2) was diagnosed with Minimal Change Disease at 15 years old, and he later developed end stage kidney disease (ESKD). Paternal grandmother (II:1) and great-grandfather (I:2) were affected by ESKD. We also found proteinuria in the sister; after few years she and her brother developed ESKD. We performed exome sequencing in III:1, III:2, IV:1, and IV:2 and we filtered a panel of 388 genes identifying a unique heterozygous variant segregating in all the affected members of NPHS2 (NM_014625:c.984del; p. Q328Hfs*20). Sanger sequencing validated it and revealed the same variant in II:1, therefore it was absent in III:3.

Discussion

We presented a tree family supporting the AD transmission of NPHS2-related glomerulopathy due to a LoF at the –C terminal. This underlines the importance of the variant itself in the genetic counseling and should point out the necessity of a periodic pipeline revision of the molecular diagnosis of the kidney disease.